326 related articles for article (PubMed ID: 31810925)
21. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
22. Using plasma cell-free DNA to monitor the chemoradiotherapy course of cervical cancer.
Tian J; Geng Y; Lv D; Li P; Cordova M; Liao Y; Tian X; Zhang X; Zhang Q; Zou K; Zhang Y; Zhang X; Li Y; Zhang J; Ma Z; Shao Y; Song L; Owen GI; Li T; Liu R; Liu Q; Zou L; Zhang Z; Li Z
Int J Cancer; 2019 Nov; 145(9):2547-2557. PubMed ID: 30919951
[TBL] [Abstract][Full Text] [Related]
23. Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid.
van der Sluis K; van Sandick JW; Vollebergh MA; van Dieren JM; Hugen N; Hartemink KJ; Veenhof AAFA; Verhoeven E; van den Berg JG; Snaebjornsson P; Noe M; van Wezel T; Boelens MC; Kodach LL
Oncogene; 2024 Jun; 43(24):1877-1882. PubMed ID: 38654110
[TBL] [Abstract][Full Text] [Related]
24. Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA.
Weerts MJA; van Marion R; Helmijr JCA; Beaufort CM; Krol NMG; Trapman-Jansen AMAC; Dinjens WNM; Sleijfer S; Jansen MPHM; Martens JWM
Sci Rep; 2017 May; 7(1):2136. PubMed ID: 28522829
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
[TBL] [Abstract][Full Text] [Related]
26. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
27. A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.
Cario CL; Chen E; Leong L; Emami NC; Lopez K; Tenggara I; Simko JP; Friedlander TW; Li PS; Paris PL; Carroll PR; Witte JS
BMC Cancer; 2020 Aug; 20(1):820. PubMed ID: 32859160
[TBL] [Abstract][Full Text] [Related]
28. Strategies for improving detection of circulating tumor DNA using next generation sequencing.
Tébar-Martínez R; Martín-Arana J; Gimeno-Valiente F; Tarazona N; Rentero-Garrido P; Cervantes A
Cancer Treat Rev; 2023 Sep; 119():102595. PubMed ID: 37390697
[TBL] [Abstract][Full Text] [Related]
29. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S
Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837
[TBL] [Abstract][Full Text] [Related]
30. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.
Lenaerts L; Vandenberghe P; Brison N; Che H; Neofytou M; Verheecke M; Leemans L; Maggen C; Dewaele B; Dehaspe L; Vanderschueren S; Dierickx D; Vandecaveye V; Amant F; Vermeesch JR
Ann Oncol; 2019 Jan; 30(1):85-95. PubMed ID: 30371735
[TBL] [Abstract][Full Text] [Related]
31. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid.
Mehrotra M; Singh RR; Chen W; Huang RSP; Almohammedsalim AA; Barkoh BA; Simien CM; Hernandez M; Behrens C; Patel KP; Routbort MJ; Broaddus RR; Medeiros LJ; Wistuba II; Kopetz S; Luthra R
J Mol Diagn; 2017 Jul; 19(4):514-524. PubMed ID: 28506684
[TBL] [Abstract][Full Text] [Related]
32. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
33. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
34. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
[TBL] [Abstract][Full Text] [Related]
35. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
36. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
[TBL] [Abstract][Full Text] [Related]
37. Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer.
Peled M; Agassi R; Czeiger D; Ariad S; Riff R; Rosenthal M; Lazarev I; Novack V; Yarza S; Mizrakli Y; Douvdevani A
Sci Rep; 2020 Sep; 10(1):14601. PubMed ID: 32884019
[TBL] [Abstract][Full Text] [Related]
38. Targeting the Sequences of Circulating Tumor DNA of Cholangiocarcinomas and Its Applications and Limitations in Clinical Practice.
Kim KH; Yi HS; Lee H; Bae GE; Yeo MK
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108676
[TBL] [Abstract][Full Text] [Related]
39. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
40. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.
Pairawan S; Hess KR; Janku F; Sanchez NS; Mills Shaw KR; Eng C; Damodaran S; Javle M; Kaseb AO; Hong DS; Subbiah V; Fu S; Fogelman DR; Raymond VM; Lanman RB; Meric-Bernstam F
Clin Cancer Res; 2020 Apr; 26(8):1924-1931. PubMed ID: 31852833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
